Nephroprotective Effects of Silymarin: A Systematic Review and Meta-Analysis
Authors:
- Negin FrounchiNFNegin Frounchi
- Fariba MahmoodpoorFMFariba Mahmoodpoor
- Seyed Sina ZakaviSZSeyed Sina Zakavi
- Kamala EyvazovaKEKamala Eyvazova
- Samira YagubovaSYSamira Yagubova
- Mohammadreza ArdalanMAMohammadreza Ardalan
- Elham AhmadianEAElham Ahmadian
- Ilgiz GareevIlgiz Gareev
- Ozal BeylerliOBOzal Beylerli
- Sergey RoumiantsevSRSergey Roumiantsev
- 29 August 2025
- journal article
- review article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 90 (8) , 1140-1152
Abstract
Kidney dysfunction could impose a heavy burden on patients and society by progressing to chronic kidney disease (CKD) and end-stage renal disease, which emphasizes the importance of a search for novel agents capable of slowing down kidney disease progression or ameliorating disease outcome in patients. One of the candidates for nephroprotective agents is silymarin, a flavonoid with the anti-oxidant and anti-inflammatory properties from the milk thistle plant. We performed a systematic review of articles from Scopus, PubMed, and Web of Science that compared the nephroprotective effects of silymarin in treated and control groups (studies conducted in animals or cells were excluded). We also performed a meta-analysis of changes in the serum creatinine level and ran a subgroup analysis on the silymarin dosage, treatment duration, patients’ age, and type of kidney disease. Quality assessment of the articles was performed with the ROB2 tool. We identified 10 relevant clinical trials; meta-analysis was performed on 7 studies and showed a significant effect of silymarin on the reduction of serum creatinine levels (Hedges’ g, −1.23; 95% CI, −2.02 to −0.43; p = 0.0024; I2 = 93.40%). Analysis of the subgroups revealed a significant creatinine reduction in patients with the drug-induced acute kidney injury (AKI) (p = 0.003), but not with CKD (p = 0.3065). The daily silymarin dose of 280 mg was ineffective (p = 0.2375) in reducing the creatinine levels. Despite the limitations, such as a small number of analyzed articles and their heterogeneity, we found that silymarin administration in the drug-induced AKI could provide a nephroprotective effect by lowering the serum levels of creatinine.Keywords
This publication has 43 references indexed in Scilit:
- Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysisPhytotherapy Research, 2024
- Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements, 2022
- A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animalsVeterinary Medicine and Science, 2021
- Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER StressCurrent Hypertension Reports, 2020
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Oxidative stress in chronic kidney diseasePediatric Nephrology, 2018
- Addition of silymarin to renin–angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trialInternational Urology and Nephrology, 2017
- Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double‐Blinded, Placebo‐Controlled Clinical TrialPhytotherapy Research, 2015
- Milk thistle in liver diseases: past, present, futurePhytotherapy Research, 2010
- Silybum marianum (L.) Gaertn: the Source of Silymarin2008